Wet AMD is currently treated with regular, invasive, intravitreal injections of anti-VEGF biological drugs, such as ranibizumab, bevacizumab, and aflibercept,6 which bind to and neutralize VEGF,6 reducing CNV and slowing vision loss. The gene discussed is VEGFA; the disease is age-related macular degeneration.